Samsung Medison, an affiliate of Samsung Electronics and a global medical equipment company, has entered an agreement for the acquisition of France-based foetal ultrasound AI software company Sonio.

The deal is valued at about $92.4m, reported Reuters.

The acquisition is expected to strengthen Samsung's position in the medical device sector by integrating AI into its ultrasound systems.

Established in 2020, Sonio has developed IT solutions and AI assistant features for obstetrics and gynaecology ultrasound, aiding medical professionals in evaluating and documenting ultrasound exams.

The company’s FDA 510(k) cleared AI assistant, Sonio Detect, utilises deep learning networks to enhance image quality in real-time and improve clinical accuracy, thus elevating the quality of care.

Samsung Medison CEO Yong Kwan Kim said: “Through the acquisition of Sonio, Samsung Medison will continue to deliver upon our promise to improve the quality of people’s lives with technology.

“Collaboration with Sonio will bring together best-in-class ultrasound AI technology and reporting capabilities to bring a paradigm shift in the prenatal ultrasound exam.”

The transaction is subject to necessary regulatory approvals, including that of the French Ministry of the Economy and Finance.

The combination of Samsung Medison’s ultrasound systems and Sonio’s AI expertise is expected to bring about breakthrough AI-enhanced workflows and innovation in patient outcomes.

Sonio will continue to operate as an independent company based in France and ensure its products and services will comply with all ultrasound device manufacturers.

Sonio CEO Cécile Brosset said: “Samsung Medison’s established global ultrasound business combined with Sonio’s advanced AI creates an exciting growth opportunity for both sides.

“In addition to close collaboration with Samsung Medison, as an independent company, Sonio will continue to advance medical reporting technology and diagnostic software globally, including for underserved areas in healthcare.”